CN110312732A - 包含pedf-衍生的短肽的组合物及其用途 - Google Patents

包含pedf-衍生的短肽的组合物及其用途 Download PDF

Info

Publication number
CN110312732A
CN110312732A CN201780075291.2A CN201780075291A CN110312732A CN 110312732 A CN110312732 A CN 110312732A CN 201780075291 A CN201780075291 A CN 201780075291A CN 110312732 A CN110312732 A CN 110312732A
Authority
CN
China
Prior art keywords
xaa
amino acid
misc
feature
naturally occurring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780075291.2A
Other languages
English (en)
Chinese (zh)
Inventor
李文机
林冠吟
曹友平
何宗权
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Quanfu Biotechnology Co Ltd
Original Assignee
Quanfu Biotechnology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quanfu Biotechnology Co Ltd filed Critical Quanfu Biotechnology Co Ltd
Publication of CN110312732A publication Critical patent/CN110312732A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CN201780075291.2A 2016-10-07 2017-08-24 包含pedf-衍生的短肽的组合物及其用途 Pending CN110312732A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662405522P 2016-10-07 2016-10-07
US62/405,522 2016-10-07
PCT/US2017/048340 WO2018067244A1 (en) 2016-10-07 2017-08-24 Compositions comprising pedf-derived short peptides and uses thereof

Publications (1)

Publication Number Publication Date
CN110312732A true CN110312732A (zh) 2019-10-08

Family

ID=61831898

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780075291.2A Pending CN110312732A (zh) 2016-10-07 2017-08-24 包含pedf-衍生的短肽的组合物及其用途

Country Status (10)

Country Link
US (1) US11760784B2 (https=)
EP (1) EP3596104A4 (https=)
JP (2) JP7573967B2 (https=)
KR (2) KR20230169375A (https=)
CN (1) CN110312732A (https=)
AU (2) AU2017340245B2 (https=)
EA (1) EA037698B1 (https=)
IL (1) IL265796B2 (https=)
TW (1) TWI878203B (https=)
WO (2) WO2018067244A1 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112206312A (zh) * 2020-11-19 2021-01-12 北京大学第三医院（北京大学第三临床医学院） 一种包含pedf的用于治疗干眼的药物组合物
CN112672731A (zh) * 2018-04-08 2021-04-16 全福生物科技股份有限公司 Pedf衍生的短肽在治疗骨关节炎中的应用
CN113038929A (zh) * 2018-04-08 2021-06-25 全福生物科技股份有限公司 Pedf衍生的短肽在肌腱愈合中的应用
WO2022242695A1 (zh) * 2021-05-19 2022-11-24 远大医药（中国）有限公司 包含pedf衍生的短肽的组合物及其制备方法和用途

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3773493A4 (en) * 2018-05-04 2022-03-30 Brim Biotechnology, Inc. PEDF DERIVED PEPTIDES TO PROMOTE MEIBOMIUS GLAND REGENERATION AND THEIR USES
CN111632128B (zh) * 2019-02-14 2022-07-05 三凡生技研发股份有限公司 短链胜肽组合物在预防或治疗干眼症的应用
TWI759610B (zh) * 2019-06-27 2022-04-01 晶碩光學股份有限公司 具有角膜修護功能的眼用產品
TWI744683B (zh) * 2019-08-27 2021-11-01 台灣基督長老教會馬偕醫療財團法人馬偕紀念醫院 短合成胜肽及其治療視網膜退化性疾病和/或組織損傷的用途
AU2019463840B2 (en) * 2019-08-27 2023-03-09 Mackay Memorial Hospital Short synthetic peptide and their uses for treating retinal degenerative diseases and/or tissue injuries
IL291929B1 (en) * 2019-10-06 2026-02-01 Brim Biotechnology Inc Preparations including short peptides derived from PEDF and their uses
WO2023244618A1 (en) * 2022-06-13 2023-12-21 Brim Biotechnology, Inc. Compositions comprising pedf-derived short peptides for the treatment of dry eye diseases
TW202400628A (zh) * 2022-06-24 2024-01-01 全福生物科技股份有限公司 用於治療神經營養性角膜炎疾病之包含pedf衍生短肽之組合物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102690344A (zh) * 2011-03-23 2012-09-26 财团法人台湾基督长老教会马偕纪念社会事业基金会马偕纪念医院 色素上皮衍生因子衍生的多肽对于促进干细胞增殖与伤口愈合的用途
CN104854129A (zh) * 2012-08-09 2015-08-19 财团法人台湾基督长老教会马偕纪念社会事业基金会马偕纪念医院 色素上皮衍生因子衍生之多肽于促进肌肉或肌腱再生或动脉血管生成的用途
CN104903346A (zh) * 2012-09-19 2015-09-09 财团法人台湾基督长老教会马偕纪念社会事业基金会马偕纪念医院 Pedf衍生的多肽在预防和/或缓和皮肤老化中的用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6451763B1 (en) * 1992-06-04 2002-09-17 The United States Of America As Represented By The Department Of Health And Human Services Retinal pigmented epithelium derived neurotrophic factor and methods of use
US6797691B1 (en) * 1997-07-23 2004-09-28 Northwestern University Methods and compositions for inhibiting angiogenesis
EP1684692A2 (en) * 2003-10-29 2006-08-02 The Johns Hopkins University Pigment epithelium-derived factor, novel biological activity and methods of use
WO2005089811A1 (en) * 2004-03-12 2005-09-29 Genvec, Inc. Materials for treating vascular leakage in the eye
EP1986676A4 (en) * 2006-02-15 2009-11-04 Univ Yale Inc COMPOSITIONS AND METHODS FOR USE OF PEDF (PIGMENT-BASED EPITHELIC DERIVED FACTOR) PEPTIDE FRAGMENTS
WO2009134339A2 (en) * 2008-04-29 2009-11-05 Monsanto Technology, Llc Genes and uses for plant enhancement
JP2013507373A (ja) * 2009-10-08 2013-03-04 ニューロテック ユーエスエー， インコーポレイテッド 被包された細胞ベースの送達系におけるｐｅｄｆの使用
TWI554521B (zh) * 2011-10-19 2016-10-21 台灣基督長老教會馬偕醫療財團法人馬偕紀念醫院 色素上皮衍生因子衍生之多胜肽於治療禿髮和／或毛髮脫色之用途
KR101770252B1 (ko) * 2012-09-20 2017-08-22 맥케이 메모리얼 호스피탈 골관절염을 치료하기 위해 사용되는 pedf-유도 폴리펩티드의 용도
WO2015038891A2 (en) * 2013-09-13 2015-03-19 The Penn State Research Foundation Functional peptide analogs of pedf

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102690344A (zh) * 2011-03-23 2012-09-26 财团法人台湾基督长老教会马偕纪念社会事业基金会马偕纪念医院 色素上皮衍生因子衍生的多肽对于促进干细胞增殖与伤口愈合的用途
US20120245097A1 (en) * 2011-03-23 2012-09-27 Yeou-Ping Tsao Use of pedf-derived polypeptides for promoting stem cells proliferation and wound healing
CN104854129A (zh) * 2012-08-09 2015-08-19 财团法人台湾基督长老教会马偕纪念社会事业基金会马偕纪念医院 色素上皮衍生因子衍生之多肽于促进肌肉或肌腱再生或动脉血管生成的用途
CN104903346A (zh) * 2012-09-19 2015-09-09 财团法人台湾基督长老教会马偕纪念社会事业基金会马偕纪念医院 Pedf衍生的多肽在预防和/或缓和皮肤老化中的用途

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112672731A (zh) * 2018-04-08 2021-04-16 全福生物科技股份有限公司 Pedf衍生的短肽在治疗骨关节炎中的应用
CN113038929A (zh) * 2018-04-08 2021-06-25 全福生物科技股份有限公司 Pedf衍生的短肽在肌腱愈合中的应用
CN112206312A (zh) * 2020-11-19 2021-01-12 北京大学第三医院（北京大学第三临床医学院） 一种包含pedf的用于治疗干眼的药物组合物
WO2022242695A1 (zh) * 2021-05-19 2022-11-24 远大医药（中国）有限公司 包含pedf衍生的短肽的组合物及其制备方法和用途

Also Published As

Publication number Publication date
WO2018067217A3 (en) 2019-05-02
IL265796A (en) 2019-06-30
EP3596104A1 (en) 2020-01-22
TW201822785A (zh) 2018-07-01
AU2017340245A1 (en) 2019-05-23
JP2019533722A (ja) 2019-11-21
IL265796B1 (en) 2024-10-01
IL265796B2 (en) 2025-02-01
JP2022185042A (ja) 2022-12-13
WO2018067217A2 (en) 2018-04-12
KR20190066030A (ko) 2019-06-12
TWI878203B (zh) 2025-04-01
US20190248859A1 (en) 2019-08-15
KR20230169375A (ko) 2023-12-15
EP3596104A4 (en) 2021-02-17
WO2018067244A1 (en) 2018-04-12
JP7573967B2 (ja) 2024-10-28
US11760784B2 (en) 2023-09-19
EA201990885A1 (ru) 2019-08-30
AU2017340245B2 (en) 2022-07-21
EA037698B1 (ru) 2021-05-12
AU2022204557A1 (en) 2022-07-21

Similar Documents

Publication Publication Date Title
CN110312732A (zh) 包含pedf-衍生的短肽的组合物及其用途
JP5122278B2 (ja) 眼細胞生存の促進におけるラクリチンの使用
US20200174017A1 (en) Compositions and methods for treating eye infections and disease
US20240123032A1 (en) Compositions and methods for prevention and treatment of corneal haze and scarring
Lin et al. Serine protease inhibitor A3K suppressed the formation of ocular surface squamous metaplasia in a mouse model of experimental dry eye
US20210386837A1 (en) Active low molecular weight variants of angiotensin converting enzyme 2 (ace2) for the treatment of diseases and conditions of the eye
JP2024059784A (ja) マイボーム腺再生を促進するためのｐｅｄｆ由来ペプチドおよびその使用
US20240082342A1 (en) Peptide therapeutics for increasing lung cell viability
Powell et al. Mild fluid percussion injury induces diffuse axonal damage and reactive synaptic plasticity in the mouse olfactory bulb
KR101567921B1 (ko) Ｏｔｘ２ 단백질을 유효성분으로 포함하는 미토콘드리아 이상질환 예방 및 치료용 조성물
Elsässer et al. Immunohistochemical demonstration of villin in the normal human pancreas and in chronic pancreatitis
CN107428805A (zh) 短合成肽及其治疗和/或预防干眼症的用途
US20250302913A1 (en) Lacripep promotes neuroregeneration and maintains epithelial progenitor cell identity
US12221494B2 (en) Short synthetic peptides and their uses for treating retinal degenerative diseases and/or tissue injuries
US20180256690A1 (en) Protection and sealing of the ocular surface barrier by clusterin
Dong et al. Restoring cardiolipin homeostasis mitigates cerebral ischemia–reperfusion injury by suppressing ATG5-mediated neuronal autophagy-dependent ferroptosis
KR20140046781A (ko) 보체인자 ｈ를 포함하는 맥락막 신생혈관 생성 예방 또는 치료용 조성물

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination